Received Jul 18, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | 57H54 | SC |
Menveo, it was administered subcutaneously instead of intramuscularly; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of intramuscular formulation administered by other route in a 23-year-old female patient who received Men ACWY-CRM NVS (Menveo) (batch number 57H54, expiry date 31-JAN-2026) for an unknown indication. On 03-JUL-2025, the patient received Menveo (subcutaneous). On 03-JUL-2025, an unknown time after receiving Menveo, the patient experienced intramuscular formulation administered by other route (Verbatim: Menveo, it was administered subcutaneously instead of intramuscularly). The outcome of the intramuscular formulation administered by other route was not applicable. Additional Information: GSK Receipt Date: 08-JUL-2025 The pharmacist reported that a patient who was administered one of vaccines, the Menveo, it was administered subcutaneously instead of intramuscularly, which led to intramuscular formulation administered by other route The Vaccine Administration Facility was the same as Primary Reporter